NASDAQ:THMO ThermoGenesis (THMO) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free THMO Stock Alerts $0.68 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.68▼$0.7550-Day Range$0.62▼$1.0952-Week Range$0.36▼$2.44Volume7,822 shsAverage Volume25,006 shsMarket Capitalization$2.14 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get ThermoGenesis alerts: Email Address ThermoGenesis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside635.3% Upside$5.00 Price TargetShort InterestHealthy1.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.35) to $0.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.90 out of 5 stars 3.5 Analyst's Opinion Consensus RatingThermoGenesis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageThermoGenesis has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.17% of the float of ThermoGenesis has been sold short.Short Interest Ratio / Days to CoverThermoGenesis has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ThermoGenesis has recently decreased by 3.99%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldThermoGenesis does not currently pay a dividend.Dividend GrowthThermoGenesis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for THMO. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for THMO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ThermoGenesis insiders have not sold or bought any company stock.Percentage Held by Insiders78.00% of the stock of ThermoGenesis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.78% of the stock of ThermoGenesis is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ThermoGenesis are expected to grow in the coming year, from ($4.35) to $0.08 per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About ThermoGenesis Stock (NASDAQ:THMO)ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.Read More THMO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart THMO Stock News HeadlinesFebruary 27, 2024 | finance.yahoo.comThermoGenesis Holdings, Inc. (NASDAQ:THMO) Is About To Turn The CornerJanuary 10, 2024 | thestreet.comThermoGenesis Holdings, Inc.April 27, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…December 16, 2023 | benzinga.comThermoGenesis Holdings Stock (NASDAQ:THMO) Dividends: History, Yield and DatesDecember 8, 2023 | finance.yahoo.comShareholders Will Probably Hold Off On Increasing ThermoGenesis Holdings, Inc.'s (NASDAQ:THMO) CEO Compensation For The Time BeingNovember 21, 2023 | benzinga.comThermoGenesis Holdings Recent Insider ActivityNovember 15, 2023 | finanznachrichten.deThermoGenesis Holdings, Inc.: ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 14, 2023 | finance.yahoo.comThermoGenesis Holdings, Inc. (NASDAQ:THMO) Q3 2023 Earnings Call TranscriptApril 27, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…November 13, 2023 | finance.yahoo.comThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 12, 2023 | msn.comThermoGenesis Q3 Earnings PreviewNovember 12, 2023 | markets.businessinsider.comHere's what Wall Street expects from ThermoGenesis's earnings reportNovember 12, 2023 | morningstar.comThermoGenesis Holdings Inc THMONovember 10, 2023 | benzinga.comThermoGenesis Holdings Earnings PreviewNovember 8, 2023 | finance.yahoo.comThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide a Corporate Strategic UpdateOctober 27, 2023 | bizjournals.comThermoGenesis opens shared lab space for immunotherapy medical startupsOctober 26, 2023 | finance.yahoo.comThermoGenesis to Open a New 35,500 Square Foot ReadyStart-IncuStart cGMP Facility in Greater SacramentoSeptember 6, 2023 | finance.yahoo.comThermoGenesis Holdings to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 12, 2023 | finance.yahoo.comThermoGenesis Holdings, Inc. (NASDAQ:THMO) Q2 2023 Earnings Call TranscriptAugust 11, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on ThermoGenesis Holdings (THMO)August 11, 2023 | finanznachrichten.deThermoGenesis Holdings, Inc.: ThermoGenesis Holdings Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 11, 2023 | finance.yahoo.comThermoGenesis Holdings Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 8, 2023 | finance.yahoo.comThermoGenesis Holdings to Announce Financial Results for the Second Quarter ended June 30, 2023 and Provide a Corporate Strategic UpdateJuly 29, 2023 | fool.comThermoGenesis (NASDAQ: THMO)July 17, 2023 | finance.yahoo.comThermoGenesis Expands Board of Directors with the Appointments of Dr. Biao Xi and Dr. James XuMay 17, 2023 | msn.comHC Wainwright & Co. Reiterates ThermoGenesis Holdings (THMO) Buy RecommendationMay 16, 2023 | finanznachrichten.deThermoGenesis Holdings, Inc.: ThermoGenesis Holdings Announces First Quarter 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive THMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ThermoGenesis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today4/27/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Laboratory apparatus & furniture Sub-IndustryN/A Current SymbolNASDAQ:THMO CUSIPN/A CIK811212 Webwww.thermogenesis.com Phone(916) 858-5100Fax916-858-5199Employees40Year Founded1986Price Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+635.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,980,000.00 Net Margins-190.31% Pretax Margin-200.31% Return on Equity-1,001.64% Return on Assets-113.62% Debt Debt-to-Equity RatioN/A Current Ratio0.44 Quick Ratio0.32 Sales & Book Value Annual Sales$9.44 million Price / Sales0.23 Cash FlowN/A Price / Cash FlowN/A Book Value($1.14) per share Price / Book-0.60Miscellaneous Outstanding Shares3,140,000Free Float690,000Market Cap$2.14 million OptionableNot Optionable Beta2.41 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Xiaochun Xu M.B.A. (Age 53)Ph.D., Chairman of the Board & CEO Comp: $699kMr. Jeffery Cauble CPA (Age 51)CFO & Corporate Secretary Comp: $325kMs. Haihong Zhu (Age 58)Chief Operating Officer Comp: $554kKey CompetitorsSalarius PharmaceuticalsNASDAQ:SLRXNotable LabsNASDAQ:NTBLCNS PharmaceuticalsNASDAQ:CNSPReShape LifesciencesNASDAQ:RSLSNanoVibronixNASDAQ:NAOVView All CompetitorsInsidersXiaochun XuSold 600,000 sharesTotal: $612,000.00 ($1.02/share)View All Insider Transactions THMO Stock Analysis - Frequently Asked Questions Should I buy or sell ThermoGenesis stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ThermoGenesis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" THMO shares. View THMO analyst ratings or view top-rated stocks. What is ThermoGenesis' stock price target for 2024? 1 analysts have issued 12-month target prices for ThermoGenesis' shares. Their THMO share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 635.3% from the stock's current price. View analysts price targets for THMO or view top-rated stocks among Wall Street analysts. How have THMO shares performed in 2024? ThermoGenesis' stock was trading at $0.6010 at the beginning of 2024. Since then, THMO stock has increased by 13.1% and is now trading at $0.68. View the best growth stocks for 2024 here. Are investors shorting ThermoGenesis? ThermoGenesis saw a decline in short interest in March. As of March 31st, there was short interest totaling 55,200 shares, a decline of 31.3% from the March 15th total of 80,400 shares. Based on an average daily trading volume, of 86,100 shares, the short-interest ratio is presently 0.6 days. Currently, 3.1% of the company's shares are sold short. View ThermoGenesis' Short Interest. When is ThermoGenesis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our THMO earnings forecast. How were ThermoGenesis' earnings last quarter? ThermoGenesis Holdings, Inc. (NASDAQ:THMO) announced its quarterly earnings data on Friday, November, 12th. The company reported ($6.75) earnings per share for the quarter, missing the consensus estimate of ($3.60) by $3.15. The firm had revenue of $3.16 million for the quarter, compared to the consensus estimate of $3.06 million. ThermoGenesis had a negative net margin of 190.31% and a negative trailing twelve-month return on equity of 1,001.64%. During the same period in the previous year, the firm earned ($16.65) earnings per share. When did ThermoGenesis' stock split? ThermoGenesis shares reverse split before market open on Friday, December 23rd 2022. The 1-45 reverse split was announced on Friday, December 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of ThermoGenesis own? Based on aggregate information from My MarketBeat watchlists, some companies that other ThermoGenesis investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), Co-Diagnostics (CODX), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Pfizer (PFE) and AbbVie (ABBV). How do I buy shares of ThermoGenesis? Shares of THMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:THMO) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe World's First "$20 Trillion Drug?"Behind the MarketsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ThermoGenesis Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
